Table 3 FDA-approved chemotherapy and immunotherapy combination
From: Combination strategies to maximize the benefits of cancer immunotherapy
Cancer | Line of therapy | Chemotherapy | Immunotherapy | Clinical benefit | Statistics | Trial name and reference |
|---|---|---|---|---|---|---|
NSCLC-non-squamous | Metastatic, first-line | Pemetrexed + platinum | Pembrolizumab | OS at 12 Mos: 69.2% versus 49.4% | HR 0.49; 95% CI 0.38–0.64; P < 0.001 | KEYNOTE-189 [50], |
NSCLC-non-squamous | Metastatic, first-line | Carboplatin + nabpaclitaxel | Atezolizumab | OS: 18.6 versus 13.9 Mos | HR 0·79; 95% CI 0·64–0·98; p = 0·033 | IMpower 130, [51] |
NSCLC-non-squamous | Metastatic, first-line | Carboplatin + paclitaxel + bevacizumab | Atezolizumab | OS: 19.2 versus 14.7 mo | HR 0.78; 95% CI 0.64 to 0.96; P = 0.02 | IMpower 150, [297] |
NSCLC | Metastatic, first-line | Platinum doublet | Nivolumab + ipilimumab | OS 15.6 versus 10.9 m; | HR 0.66; 95% CI 0.55–0.80; P = 0.00065 | CheckMate-9LA, [299] |
NSCLC-squamous | Metastatic, first-line | Carboplatin + paclitaxel/ nabpaclitaxel | Pembrolizumab | OS: 15.9 versus 11.3 months | HR 0.64; 95% CI 0.49 to 0.85; P < 0.001 | KEYNOTE-407, [52] |
SCLC | Extensive stage, first-line | Carboplatin + etoposide | Atezolizumab concurrent and maintenance | OS: 12.3 versus 10.3 m | HR 0.70; 95% CI 0.54–0.91; P = 0.007 | IMpower133, [53] |
SCLC | Extensive stage, first-line | Carboplatin + etoposide | Durvalumab | OS: 12.9 versus 10.5 months | HR 0·73 (95% CI 0·59–0·91; p = 0·0047 | CASPIAN, [54] |
Breast triple negative | Metastatic, first-line | nabpaclitaxel | Atezolizumab | OS: 25.0 versus 15.5 months (PD-L1( +) | HR 0.62; 95% CI 0.45–0.86 | IMpassion 130, [55] |
Breast triple negative | Metastatic, first-line | Nabpaclitaxel or paclitaxel or carbpolatin + Gemcitabine | Pembrolizumab | PFS (CPS > 10) 9.7 versus 5.6 m: | HR 0·65, 95% CI 0·49–0·86; one-sided p = 0·0012 | KEYNOTE 355, [56] |
Bladder cancer | Metastatic, first-line maintenance | Gemcitabine + cisplatin/carboplatin | Avelumab | OS: 21.1 versus 14.3 Mo | HR 0.69; 95% CI 0.56 to 0.86; P = 0.001 | JAVELIN Bladder 100, [58] |
Head and Neck Cancer | Metastatic first-line | Platinum + 5-FU or platinum + 5-FU + cetuximab | Pembrolizumab | OS: 13·6 versus 10·4 (CPS ≥ 1) | HR 0·65; 95% CI 0·53–0·80; p < 0·0001 | KEYNOTE-048, [57] |